First-Line Capivasertib Plus Paclitaxel Fails to Improve OS in Metastatic Triple-Negative Breast Cancer
Heather McArthur, MD, UT Southwestern Medical Center, Dallas, Texas, discusses results from the phase 3 CAPItello-290 trial which evaluated capivasertib plus paclitaxel to placebo plus paclitaxel as first-line therapy in patients with metastatic triple-negative breast cancer (TNBC).
The study did not meet the primary predefined threshold for overall survival (OS) however progression-free survival (PFS) favored capivasertib plus paclitaxel and the safety profile was consistent with prior findings.
Dr McArthur presented these results at the 2024 European Society of Medical Oncology (ESMO) Congress in Barcelona, Spain.
Transcript:
My name is Heather MacArthur and I'm the Clinical Director of Breast Cancer at UT Southwestern in Dallas, Texas. I'm here at the 2024 ESMO Congress in Barcelona, Spain.
At this meeting we reported on the data from the CAPItello-290 study. This was a study that enrolled 812 patients with untreated, metastatic triple-negative breast cancer and randomized them 1-to-1 to receive paclitaxel chemotherapy with either capivasertib or placebo. Capivasertib is an oral AKT targeted molecule that targets all AKT forms, and the intention is that it inhibits that pathway. The co-primary end points for this study were overall survival in the intention-to-treat overall population as well as overall survival in the PIK3CA, AKT1, PTEN altered population.
The study did not meet the primary endpoint of overall survival in the overall population or in the altered population. There was a numerical trend for PFS and overall response rate, 2 key secondary end points, in favor of the capivasertib combination in the altered population, but overall, this was a negative study.
Source:
Schmid P, McArthur HL, Cortés J, et al. Capivasertib (C) + paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial. Presented at 2024 ESMO Congress. September 13-17, 2024. Abstract LBA19
